110-14-5

Basic information

• Product Name: SUCCINAMIDE
• Synonyms: SUCCINAMIDE;SUCCINDIAMIDE;SUCCINIC ACID AMIDE;SUCCINIC ACID DIAMIDE;SUCCINIC DIAMIDE;butanediamide;Succinic amide;Butanedioic acid diamide~Succinic diamide
• CAS NO: 110-14-5
• Molecular Formula: C₄H₈N₂O₂
• Molecular Weight: 116.12
• EINECS: 203-739-9
• Product Categories: Amides;Building Blocks;C2 to C7;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 110-14-5.mol

Chemical Properties

• Melting Point: 260-265 °C (dec.)(lit.)
• Boiling Point: 217.15°C (rough estimate)
• Flash Point: 252.6 °C
• Appearance: white to off-white fine crystalline powder
• Density: 1.2829 (rough estimate)
• Vapor Pressure: 6.7E-10mmHg at 25°C
• Refractive Index: 1.4880 (estimate)
• Storage Temp.: Store below +30°C.
• Solubility: cold water: soluble220 part
• PKA: 15.88±0.40(Predicted)
• Water Solubility: Slightly soluble in water.
• Merck: 14,8866
• BRN: 1753983
• CAS DataBase Reference: SUCCINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: SUCCINAMIDE(110-14-5)
• EPA Substance Registry System: SUCCINAMIDE(110-14-5)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 110-14-5(Hazardous Substances Data)

Usage

Uses

Used in Biotechnology Research:
SUCCINAMIDE is used as a nitrogen supplement in the culture medium of Scenedesmus obliquus and green algae, which are essential for their growth and development. This application aids in the study and cultivation of these microorganisms for various biotechnological purposes.
Used in Enzyme Characterization:
In the field of biochemistry, SUCCINAMIDE has been employed in the characterization of a novel biuret hydrolase from the cysteine hydrolase superfamily. This application helps researchers understand the enzyme's structure, function, and potential applications in various industries.

Purification Methods

Crystallise it from water. [Beilstein 2 H 614.]

InChI:InChI=1/C4H8N2O2/c5-3(7)1-2-4(6)8/h1-2H2,(H2,5,7)(H2,6,8)

Upstream product

• 123-56-8 Succinimide 
• 110-61-2 butanedinitrile 
• 110-15-6 succinic acid 
• 17384-46-2 N,N'-bis-ethoxycarbonyl-succinamide 
• 77287-34-4 formamide 
• 543-20-4 succinoyl dichloride 
• 57-13-6 urea 
• 106-65-0 Dimethyl succinate 
• 2345-56-4 Malonamic acid 
• 60-35-5 acetamide 
• 2226-88-2 diammonium succinate 
• 7664-41-7 ammonia 
• 60-29-7 diethyl ether 
• 17636-93-0 N,N'-dimethyl-N,N'-dinitroso-succinamide 

Downstream Products

• 123-56-8 Succinimide 
• 504-07-4 5,6-dhydrouracil 
• 638-32-4 succinamic acid 
• 57-13-6 urea 
• 642-04-6 2,3,5,6-tetraphenylpyrazine 
• 15510-09-5 Succinanilid 
• 35658-48-1 N'1,N'4-diphenylsuccinohydrazide 
• 108472-45-3 N,N'-Bis-[1-dimethylamino-1-phenyl-meth-(E)-ylidene]-succinamide 
• 54660-00-3 3,6-diphenyl-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-(2H,5H)-dione 
• 928-54-1 1,2-Ethylendiisocyanid 
• 81292-80-0 5-Imino-2,2-pyrrolidinylidendiphosphonsaeure 
• 25589-18-8 3-benzyl-6-methylpyrimidine-2,4(1H,3H)-dione 
• 107-95-9 3-amino propanoic acid 
• 420-05-3 cyanic acid 

Related news

SUCCINAMIDE (cas 110-14-5) derivatives of melampomagnolide B and their anti-cancer activities08/21/2019

A series of succinamide derivatives of melampomagnolide B have been synthesized by coupling MMB monosuccinate (2) with various heterocyclic amines to afford compounds 3a–3l. MMB monosuccinate was also reacted with terminal diaminoalkanes to afford dimeric succinamido analogs of MMB (4a–4h). Th...detailed

Relevant articles and documents

Reaction enthalpies for M+L = M+ + L, where M+ = Na+ and K+ and L = acetamide, N-methylacetamide, N,N-dimethylacetamide, glycine, and glycylglycine, from determinations of the collision-induced dissociation thresholds

With electrospray (ES), ions present in solution can be transferred to the gas phase. The method provides unique opportunities for studies of hitherto inaccessible ions. Collision-induced dissociation threshold measurements of gas phase ions produced by ES are described. The thresholds for the reactions M+L = M+ + L, where M+ is Na+ or K+ and L is acetone, dimethyl sulfoxide, acetamide, N-methylacetamide, N,N-dimethylacetamide, glycine, glycinamide, succinamide, and glycylglycine, were determined. Enthalpy changes for the reaction were derived from these data.

A facile hydration of nitriles into amides by Al2O3/MeSO3H (AMA)

A new and practical method for the conversion of nitriles to amides by employing the A12O3/MeSO3H (AMA) is described.

Transfer Hydration of Dinitriles to Dicarboxamides

We present a robust method for double transfer hydration of dinitriles to afford diamides. The transfer hydration of 1, n -dinitriles (n = 1-6) proceeds smoothly in the presence of a palladium(II) catalyst with acetamide as a water donor, affording the corresponding diamides in moderate to high yields, without involving significant side reactions such as monohydration or cyclization. The equilibrium was shifted in the forward direction by removing coproduced acetonitrile under reduced pressure.

Mild and selective heterogeneous catalytic hydration of nitriles to amides by flowing through manganese dioxide

A sustainable flow chemistry process for the hydration of nitriles, whereby an aqueous solution of the nitrile is passed through a column containing commercially available amorphous manganese dioxide, has been developed. The product is obtained simply by concentration of the output stream without any other workup steps. The protocol described is rapid, robust, reliable, and scalable, and it has been applied to a broad range of substrates, showing a high level of chemical tolerance.

METHOD FOR MAKING COMPLEMENTARY OLIGONUCLEOTIDE TAG SETS

The invention provides a method of synthesizing a repertoire of oligonucleotide tags comprising the steps of synthesizing a repertoire of oligonucleotide tag complements on one or more solid phase supports, cleaving a fraction of the oligonucleotide tag complements from the support(s), and inserting the cleaved tag complements into a cloning vector, as depicted in the figure. The cloned tag complements can conventionally be conjugated to selected polynucleotides to produce tagged polynucleotides having unique tag sequences which can be captured and sorted by hybridization to corresponding tag complements. Also provided are various reagents and components that are used or produced in the method.

PROCESS FOR PRODUCING N-METHYL SUCCINIMIDE

The invention includes methods of processing an initial di-carbonyl compound by conversion to a cyclic compound. The cyclic compound is reacted with an alkyating agent to form a derivative having an alkylated ring nitrogen. The invention encompasses a method of producing an N-alkyl product. Amonia content of a solution is adjusted to produce a ratio of ammonia to di-carboxylate compound of from about 1:1 to about 1.5:1. An alkylating agent is added and the initial compound is alkylated and cyclized. The invention includes methods of making N-methyl pyrrolidinone (NMP). Aqueous ammonia and succinate is introduced into a vessel and ammonia is adjusted to provide a ratio of ammonia to succinate of less than 2:1. A methylating agent is reacted with succinate at a temperature of from greater than 100 °C to about 400 °C to produce N-methyl succinimide which is purified and hydrogenated to form NMP.

Method for treating neurological disorders

Treatment or the prevention of neurological disorders in a warm-blooded mammal, by use of a compound of formula VIII wherein A, B, R2, R3, R4, R5, R8, R9and n are as defined in the specification, or pharmaceutically-acceptable salts, prodrugs or solvates thereof. Processes for the preparation of compounds of Formula VIII are described, as are pharmaceutical compositions containing them.

Lactams substituted by cyclic succinates as inhibitors of a beta protein production

This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles

A synthesis for preparing asymmetrical 1,4-diketopyrrolo[3,4-c]pyrroles involving: (a) reacting a β-ketoamide with a strong base; (b) halogenating the same or a different β-ketoamide; (c) reacting the reaction products of step (a) and (b) to form a succinamide; and (d) heating the succinamide in the presence of a Lewis Acid. Symmetrical 1,4-diketopyrrolo [3,4-c]pyrroles are synthesized by oxidatively dimerizing the reaction product of step (b) to form a succinamide; and heating the succinamide in the presence of a Lewis Acid.

RETROVIRAL PROTEASE INHIBITORS

Urea-containing hydroxyethylamine peptide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.